Report Overview:
Botulism is a rare and potentially fatal illness caused by a toxin produced by the bacterium Clostridium botulinum. The disease begins with weakness, blurred vision, feeling tired, and trouble speaking. This may then be followed by weakness of the arms, chest muscles, and legs. Vomiting, swelling of the abdomen, and diarrhea may also occur. The disease does not usually affect consciousness or cause a fever.
This report provides a deep insight into the global Botulism Illness Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Botulism Illness Drugs market size was valued at US$ 156.4 million in 2024 and is projected to reach US$ 203.7 million by 2030, at a CAGR of 4.5% during the forecast period 2024-2030.
United States Botulism Illness Drugs market size was valued at US$ 51.2 million in 2024 and is projected to US$ 64.6 million by 2030, at a CAGR of 4.0% during the forecast period 2024-2030.
CAGR of 4.5% (2022 – 2029)
By Types:
Antibiotics
Antitoxins
By Applications: Hospitals
Clinics
Others
Key players include:
•Eisai
•Microbiotix
•Including or Excluding key companies relevant to your analysis.
